Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Sorafenib increases the amount of CYLD. 2 / 2

1 | 1

➶

ctd

No evidence text available

21109933

➶

reach

"We have already shown that CYLD expression in HCC cells can be triggered by the multikinase inhibitor sorafenib, by inhibition of Raf-1, as well as by blockage of the pro survival kinases MEK and EGFR and identified the recovery of CYLD expression as an interesting approach for overcoming HCC resistance XREF_BIBR."

25329885

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...